A Phase IIb, Clinical Trial to Study the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in Participants With Advanced or Recurrent Gastric Cancer (KEYNOTE-659)
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-659
- Sponsors Merck Sharp & Dohme; Taiho Pharmaceutical Company
- 05 Apr 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 Planned initiation date changed from 2 Mar 2018 to 28 Mar 2018.
- 16 Feb 2018 Planned End Date changed from 31 Dec 2020 to 17 Aug 2020.